future of glp-1 drugs Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Drugs: The Science and

Troxatyl plus topotecan, Ara-C, or idarubicin in patients (pts) with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or blastic-phase chronic myeloid leukemia (CML-BP): A randomized phase I/II study

Consistent with previous findings [44, 45], we found that the presence of L

It does not act directly on free radicals but is a vital part of most antioxidant enzymes (metalloenzymes, glutathione peroxidase, and thioredoxin reductase) that would have no effect without it [47]

The use of a simple non-toxic metabolite like carnitine, as an anti-apoptotic agent, is very attractive compared to synthetic inhibitors with inevitable side effects [51]